Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 2 (T2DM) Clear all
Terminated Not applicable Interventional

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

NCT00743756
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
home-delivered meals, diabetes education for 12 months
Dietary Supplement · Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 4, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

OASIS: Peer Support for T2DM in Appalachia (Peer Participant)

NCT06336122
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Coach Training - Weekly, Peer Coach Training - Biweekly
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bowling Green, Kentucky • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 4, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

CGM for Management of Type 2 Diabetes in Pregnancy

NCT06628453
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Pregnancy
Interventions
CGM
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

NCT05405244
View directory record Official record
Conditions
Overweight and Obesity, Eating Behavior
Interventions
Placebo, Bromocriptine-QR
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT05134662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fort Myers, Florida • Sarasota, Florida • River Forest, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

NCT00577590
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Metformin, Rosiglitazone, Lovaza
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 4, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

NCT05199090
View directory record Official record
Conditions
Obesity
Interventions
MBL949, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Morehead City, North Carolina • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

NCT03199053
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

NCT02759107
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus (T2DM)
Interventions
Tirzepatide, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers

NCT00394030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK716155 subcutaneous injections
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Long Beach, California • Walnut Creek, California • Miramar, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 4, 2026, 10:10 AM EDT
Enrolling by invitation Not applicable Interventional

To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years

NCT07387393
View directory record Official record
Conditions
Cardiometabolic Conditions, Hypertension (HTN), Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Overweight (BMI > 25), Weight Loss Trial
Interventions
PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment

NCT07416799
View directory record Official record
Conditions
Type2diabetes, Mild Cognitive Impairment, Age-related Cognitive Decline
Interventions
Progressive Exercise Program (12 Weeks)
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 4, 2026, 10:10 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes

NCT07228208
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Endothelial Dysfunction
Interventions
MitoQ (mitoquinol mesylate), Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 4, 2026, 10:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

NCT07106879
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions
Blood Work
Other
Lead sponsor
Clindove Research LLC
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01407003
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings

NCT02643797
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Medical Assistant Health Coaching
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 4, 2026, 10:10 AM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04754334
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Effectiveness of and Implementation Strategies for 'Disfrutando'.

NCT07023406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Disfrutando
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Columbia, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 4, 2026, 10:10 AM EDT
Not listed No phase listed Observational

CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery

NCT05666479
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Interventions
Dexcom G6 Pro Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 4, 2026, 10:10 AM EDT